Physician profile
Farhan Ali
NPI 1023513397
$5,546.84
in general payments reported to CMS, 2019-2025
10 companies · $2,105 in 2025
The $2,105 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $38.84 · 2024: $3,403 · 2025: $2,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,685 · Consulting Fee: $1,980 · Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,684.86 |
| Consulting Fee | $1,980.00 |
| Food and Beverage | $881.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,253.93 | 2024-2025 | Overstitch Endoscopic Suturing System, Exalt Model D, Spyglass |
| Prenosis INC. | $1,980.00 | 2024 | Sepsis Immunoscore Tm |
| Abbvie INC. | $113.25 | 2024-2025 | |
| Olympus America INC. | $50.67 | 2025 | Visiglide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.84 | 2023 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $23.53 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.14 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $22.03 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $21.56 | 2024 | Entyvio |
| Gilead Sciences, INC. | $19.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhan Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.